Clinical guidance on rare blood clots associated with J & J Covid-19 vaccine
The U.S. Centers for Disease Control and Prevention (CDC) has released clinical guidance to assist medical professionals with identifying and treating a rare but serious type of blood clot that has developed in some patients following inoculation with the Johnson & Johnson (J & J) COVID-19 vaccine.
Concerns over the clots have prompted temporary pauses nationally in administration of the J & J vaccine. All six known cases as of April 13 have occurred in women aged 18-48. Symptoms developed between six and 13 days after vaccination, resulting in one death.